Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma.
Chiara ChiavelliMalvina PrapaGiulia RovestiMarco SilingardiGiovanni NeriGiuseppe PuglieseLucia TruduMassimiliano Dall'OraGiulia GolinelliGiulia GrisendiJonathan VinetMarco BestagnoCarlotta SpanoRoberto Vito PapapietroRoberta DepenniKatia Di EmidioAnna PasettoDaniela Nascimento SilvaAlberto FelettiSilvia BerlucchiCorrado IaccarinoGiacomo PavesiMassimo DominiciPublished in: NPJ precision oncology (2024)
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
Keyphrases
- induced apoptosis
- bone marrow
- cell therapy
- platelet rich plasma
- cell cycle arrest
- end stage renal disease
- endothelial cells
- chronic kidney disease
- newly diagnosed
- ejection fraction
- radiation therapy
- peritoneal dialysis
- endoplasmic reticulum stress
- stem cells
- combination therapy
- signaling pathway
- locally advanced
- photodynamic therapy
- cell death
- peripheral blood
- squamous cell carcinoma
- radiation induced
- oxidative stress
- pi k akt
- cancer therapy
- patient reported outcomes
- drug delivery